[an error occurred while processing this directive]|[an error occurred while processing this directive]
局部晚期NSCLC模板辅助技术192Ir源后装立体消融治疗安全性初步观察
石翔翔, 唐涛, 庞皓文, 孙小杨, 吴敬波, 林盛
西南医科大学附属医院肿瘤科,泸州 646000
Preliminary observation of the safety of template-assisted 192Ir source hypofractionated stereotactic ablative brachytherapy for locally advanced non-small cell lung cancer
Shi Xiangxiang,Tang Tao,Pang Haowen,Sun Xiaoyang,Wu Jingbo,Lin Sheng
Department of Oncology,Affiliated Hospital of Southwest Medical University,Luzhou 646000,China
Abstract：Objective To preliminarily evaluate the safety of the coplanar template-assisted 192Ir hypofractionated stereotactic ablative brachytherapy (SABT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC),and assess the effect of template-assisted technology upon the accuracy of SABTby comparing the consistency of dosimetric parameters between preoperative and operative plans. Methods Fifteen patients histologically confirmed with LA-NSCLC (stage ⅡB-ⅢA) were recruited and received the template-assisted SABT delivered in a risk-adapted fractionation (30Gy/1F). Preoperative planning, template-assisted needle implantation, operative planning and implementation were performed in all patients. Dosimetric results of preoperative and operative plans were statistically compared by assessing the dosimetric parameters of gross tumor volume (HI,CI,D90,V100 and V150) and organ at risk(V5,V20 and mean dose of bilateral lung,D2cc of spinal cord. The incidence of perioperative complications of SABT was recorded. The safety and feasibility of SABT were evaluated. Results Slight changes were noted in terms of target dose and irradiated dose to the lung between preoperative and operative plans without statistical significance (both P>0.05). No severe adverse events, such as severe pneumothorax, hemothorax and hemoptysis were observed. Conclusions Application of the template-assisted SABT can enhance the accuracy of implantation, maintain the consistency of the dosimetric parameters between the preoperative and operative plans and guarantee the clinical efficacy.
Shi Xiangxiang,Tang Tao,Pang Haowen et al. Preliminary observation of the safety of template-assisted 192Ir source hypofractionated stereotactic ablative brachytherapy for locally advanced non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2019, 28(9): 665-668.
[1] 霍彬,侯朝华,叶剑飞,等. CT引导术中实时计划对胸部肿瘤125I粒子植入治疗的价值[J]. 中华放射肿瘤学杂志,2013,22(5):400-402. DOI:10.3760/cma.j.issn.1004-4221.2013.05.019. Ho B,Hou CH,Ye JF,et al. Value of real-time planning for 125I particle implantation in thoracic tumors during CT guided surgery[J]. Chin J Radiat Oncol,2013,22(5):400-402. DOI:10.3760/cma.j.issn.1004-4221.2013.05.019. [2] 彭冉,姜玉良,吉喆,等.3D打印共面坐标模板辅助CT引导放射性125I粒子植入治疗恶性肿瘤剂量学分析[J]. 中华放射肿瘤学杂志,2017,26(9):1062-1066. DOI:10.3760/cma.j.issn.1004-4221.2017.09.016. Peng R,Jiang YL,Ji Z,et al.3D printing coplanar coordinate template assisted CT guided radioactive 125I particle implantation in the treatment of malignant tumor dosimetry[J]. Chin J Radiat Oncol,2017,26(9):1062-1066. DOI:10.3760/cma.j.issn.1004-4221.2017.09.016. [3] Xiang L,Zhang JW,Lin S,et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in combination with regional positive lymph node intensity-modulated radiation therapy in locally advanced peripheral non-small cell lung cancer:a phase 1 clinical trial[J]. Int J Radiat Oncol Biol Phys,2015,92(5):1027-1034. DOI:10.1016/j.ijrobp.2015.04.019. [4] Georg D,Hopfgartner J,Gòra J,et al. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon,proton,or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy[J]. Int J Radiat Oncol Biol Phys,2014,88(3):715-722. DOI:10.1016/j.ijrobp.2013.11.241. [5] Chi A,Wen S,Liao Z,et al. What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer[J]. Biomed Res Int,2013,2013(3):391021. DOI:10.1155/2013/391021. [6] Borst GR,Ishikawa M,Nijkamp J,et al. Radiation pneumonitis after hypofractionated radiotherapy:evaluation of the LQ (L) model and different dose parameters[J]. Int J Radiat Oncol Biol Phys,2010,77(5):1596-1603. DOI:10.1016/j.ijrobp.2009.10.015. [7] Saw CB,Suntharalingam N. Quantitative assessment of interstitial implants[J]. Int J Radiat Oncol Biol Phys,1991,20(1):135. [8] Afsharpour H,Reniers B,Landry G,et al. Consequences of dose heterogeneity on the biological efficiency of 103Pd permanent breast seed implants[J]. Phys Med Biol,2012,57(3):809-823. DOI:10.1088/0031-9155/57/3/809. [9] Feuvret L,Nol G,Mazeron JJ,et al. Conformity index:a review[J]. Int J Radiat Oncol Biol Phys,2006,64(2):333. DOI:10.1016/j.ijrobp.2005.09.028. [10] Brennan SM,Thirion P,Buckney S,et al. Factors influencing conformity index in radiotherapy for non-small cell lung cancer[J]. Med Dosim,2010,35(1):38-42. DOI:10.1016/j.meddos.2009.01.003. [11] Machtay M,Bae K,Movsas B,et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation:an analysis of the radiation therapy oncology group[J]. Int J Radiat Oncol Biol Phys,2012,82(1):425-434. DOI:10.1016/j.ijrobp.2010.09.004. [12] Baumann P,Nyman J,Hoyer M,et al. Outcome in a prospective phase Ⅱ trial of medically inoperable stage Ⅰ non-small-cell lung cancer patients treated with stereotactic body radiotherapy[J]. J Clin Oncol,2009,27(20):3290-3296. DOI:10.1200/JCO.2008.21.5681.
2019, Vol. 28 
